TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Trending·October 29, 2026

Illumina, Inc. (ILMN) falls 11.7% after Q3 revenue miss

Illumina, Inc. (ILMN) falls sharply after reporting third-quarter results that beat adjusted profit estimates but missed on revenue. The company also raised full-year guidance, yet investors focused on the sales shortfall and the stock’s extended-hours drop.

TrendingILMN
By TickerSpark·October 29, 2026·5 min read
Illumina, Inc. (ILMN) falls 11.7% after Q3 revenue miss
▌Key Takeaway
Illumina, Inc. (ILMN) falls 11.7% in after-hours trading after its third-quarter report showed a revenue miss despite an adjusted EPS beat and higher full-year guidance. The selloff suggests investors are prioritizing sales quality and growth momentum over the profit beat, which could keep pressure on the stock until regular-session trading confirms the move.

Illumina, Inc. (ILMN) falls sharply in after-hours trading after reporting third-quarter 2026 results, with the stock printing at $256 versus a $290.06 regular-session close. The decline reflects a mixed earnings picture: Illumina beat adjusted EPS estimates and raised full-year guidance, but reported revenue of $1.13 billion below analyst expectations. This is an extended-hours move, so regular-session trading will confirm whether the drop holds.

Key Takeaways

  • ILMN traded at $256 in after-hours trading, down 11.74% from the prior close of $290.06.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

The primary catalyst was Illumina’s Q3 2026 report, which showed adjusted EPS of $1.44 versus a $1.36 analyst estimate.
  • Revenue reached $1.13 billion, up 4.2% year over year, but fell short of Wall Street expectations.
  • Illumina raised full-year revenue and earnings guidance, including a $4.65 billion revenue midpoint that sits 0.6% above consensus.
  • The selloff puts valuation and revenue quality under the microscope, even though the company still holds a strong sequencing platform and recurring consumables model.
  • Why Illumina, Inc. (ILMN) Falls After Q3 Earnings

    The clearest catalyst is Illumina’s third-quarter earnings report, published after the October 29 close. The timing matches the sharp after-hours move, and no separate company-specific event in the prior 24 to 48 hours offers a stronger explanation.

    The report delivered a split verdict. Adjusted EPS came in at $1.44, above the $1.36 average estimate from five analysts surveyed by Zacks Investment Research. That result also matches coverage citing an $0.08 EPS beat. GAAP net income reached $220 million, while GAAP EPS was $1.43.

    Revenue created the problem. Illumina posted $1.13 billion, up 4.2% from the same quarter a year earlier, but news coverage reported that sales missed analyst estimates. Investors often tolerate a revenue miss when profit growth is strong. However, a revenue miss can still pressure a growth-oriented stock when the shares carry a demanding valuation.

    Broader earnings pressure in technology also added noise, with Amazon and Intel among other reported overnight losers. Still, the same-day Q3 report remains the dominant ILMN catalyst. A Stephens downgrade to Equal Weight on October 23 and a Canaccord Genuity target increase to $300 on October 19 were earlier events, not fresh explanations for this immediate move.

    Illumina Financial Results Show Profit Strength but Revenue Friction

    The underlying numbers explain why the stock reaction looks harsher than the headline earnings beat. Illumina reported $1.17 billion of revenue excluding tariff refunds. That figure increased 4.7% after excluding currency, acquisitions, and Greater China effects.

    This adjusted view shows continued growth outside the company’s most difficult areas. Yet the gap between $1.13 billion of reported revenue and $1.17 billion excluding tariff refunds highlights why investors focus on revenue quality. Greater China effects, tariffs, currency, and acquisitions complicate the headline comparison.

    Illumina also reported a 27.0% GAAP operating margin. More importantly, the company raised full-year revenue and earnings guidance based on continued momentum. The full-year revenue midpoint of $4.65 billion stands 0.6% above analyst consensus.

    That guidance increase gives investors a constructive forward signal. At the same time, the market’s response shows that guidance alone did not offset concern about quarterly sales. In plain English, management improved the destination, but investors disliked part of the road taken to get there.

    ILMN Valuation and Competitive Position After the Drop

    Illumina’s financial profile gives the selloff additional importance. The company has a $43.80 billion market capitalization and a P/E of 53.8787. That multiple leaves less room for revenue execution problems than a lower-valued stock would have.

    The shares have traded between $106.12 and $309.35 over the past 52 weeks. The $256 after-hours price sits near the $252.73 analyst consensus target and the $260 median target. Those figures do not determine fair value, but they show that the post-earnings price is close to the central range of published targets.

    The business still has meaningful competitive advantages. Illumina sells sequencing and microarray instruments, consumables, software, and services. Its installed base supports recurring demand for reagents, flow cells, and library preparation products.

    The company also serves genomic research centers, hospitals, pharmaceutical companies, biotechnology firms, and diagnostic laboratories. That customer reach supports Illumina’s long-term position. However, competition, pricing pressure, China-related regulatory risk, and execution risk remain material constraints.

    What the ILMN Earnings Drop Means for Investors

    The practical takeaway is to separate the earnings signal from the trading reaction. The earnings signal is mixed, not uniformly negative. Illumina beat adjusted EPS estimates, delivered a 27.0% GAAP operating margin, and raised full-year guidance. The negative signal is the $1.13 billion revenue result and the market’s sharp response to that shortfall.

    A disciplined investor can use three reference points. First, compare the $1.13 billion reported revenue with the $1.17 billion figure excluding tariff refunds. Second, weigh the $4.65 billion guidance midpoint against the quarterly sales miss. Third, judge whether the $256 after-hours price makes the 53.8787 P/E more attractive relative to the company’s growth rate.

    The business case remains tied to clinical sequencing, consumables growth, and recovery in research demand. Recent company commentary identified clinical demand as the main growth driver while research activity continued recovering. Therefore, the raised guidance supports the long-term story, but the revenue miss shows that execution still matters greatly.

    Investors should avoid treating one after-hours print as a complete verdict on Illumina. Regular-session volume and price action will provide a better test of whether the market views the report as a temporary revenue stumble or a deeper growth concern.

    Illumina falls because Q3 revenue missed expectations, despite a $1.44 adjusted EPS beat and higher full-year guidance. The company retains a powerful sequencing platform, but its valuation demands reliable revenue execution. For investors, the central issue is whether guidance strength can outweigh near-term concerns about sales quality, China exposure, and research-market recovery.

    Read the full ILMN research report
    ▌Common Questions

    Frequently asked questions

    +Why is ILMN stock down today?
    ILMN is down because Illumina’s Q3 revenue came in below analyst expectations, even though adjusted EPS beat estimates and the company raised full-year guidance. Investors appear to be focusing on the sales miss and the quality of growth rather than the profit beat.
    +Should I buy ILMN stock now?
    The report is mixed, so this is not a clear buy-the-dip setup based on the earnings reaction alone. Investors may want to wait for regular-session confirmation and more clarity on whether the revenue miss was a one-quarter issue or a broader growth concern.
    +Did Illumina beat earnings expectations?
    Yes. Illumina reported adjusted EPS of $1.44, above the $1.36 analyst estimate. However, the stock still fell because revenue missed expectations.
    +What does the guidance raise mean for ILMN investors?
    The higher guidance is a constructive sign because management sees stronger full-year performance ahead. Even so, the market is signaling that investors want to see better quarterly revenue execution before rewarding the stock.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on ILMN?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the ILMN report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full ILMN research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the ILMN report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on ILMN

    More to read

    All articles
    Illumina, Inc. (ILMN) falls 13% After Q3 Earnings
    ILMN

    Illumina, Inc. (ILMN) falls 13% After Q3 Earnings

    Illumina, Inc. (ILMN) falls after-hours after its Q3 report, even as the company raised full-year guidance. Investors are focusing on a slight revenue miss, China-related pressure, and a premium valuation that leaves little room for disappointment.

    Oct 30·5 min
    Illumina (ILMN): Clinical Sequencing Rebuild Gains Traction
    ILMN

    Illumina (ILMN): Clinical Sequencing Rebuild Gains Traction

    Illumina is rebuilding growth around clinical sequencing, NovaSeq X consumables, and multi-omics, but valuation keeps the stock in Hold territory. Q3 results and raised guidance show momentum, yet the shares already price in much of the recovery.

    Oct 29·17 min
    Illumina, Inc. (ILMN) rises on S&P 500 inclusion
    ILMN

    Illumina, Inc. (ILMN) rises on S&P 500 inclusion

    Illumina, Inc. (ILMN) rises after S&P Dow Jones Indices confirmed the company will join the S&P 500 on Sep. 21. The stock also drew support from solid Q2 results, raised full-year guidance, and heavier trading volume, though shares now sit above consensus analyst targets.

    Sep 15·5 min